BRPI0414604A - combinations of a vegf receptor inhibitor with other therapeutic agents - Google Patents

combinations of a vegf receptor inhibitor with other therapeutic agents

Info

Publication number
BRPI0414604A
BRPI0414604A BRPI0414604-2A BRPI0414604A BRPI0414604A BR PI0414604 A BRPI0414604 A BR PI0414604A BR PI0414604 A BRPI0414604 A BR PI0414604A BR PI0414604 A BRPI0414604 A BR PI0414604A
Authority
BR
Brazil
Prior art keywords
inhibitors
therapeutic agents
combinations
receptor antagonists
vegf
Prior art date
Application number
BRPI0414604-2A
Other languages
Portuguese (pt)
Inventor
Guido Bold
Josef Bernhard Brueggen
Jerry Min-Jian Huang
Frederick Ray Kinder
Heidi Lane
Elisabeth Jeanne Latour
Paul William Manley
Jeanette Marjorie Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0414604A publication Critical patent/BRPI0414604A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)

Abstract

"COMBINAçõES DE UM INIBIDOR DO RECEPTOR DE VEGF COM OUTROS AGENTES TERAPêUTICOS". A presente invenção refere-se a uma terapia combinada para o tratamento de pacientes sofrendo de doenças caracterizadas por proliferação celular e infiltração de células inflamatórias, doenças coronarianas, hipertensão, doenças renais, diabetes ou doenças e condições oculares. O paciente é tratado com uma combinação de: (a) um composto inibidor de VEGF; e (b) um ou mais segundos agentes terapêuticos selecionados do grupo consistindo em: i. esteróides angiostáticos; ii. fotossensibilizantes; iii. implantes contendo corticosteróides; iv. antagonistas do receptor AT1; v. inibidores de ACE; vi. inibidores de ciclooxigenase; vii. inibidores de IGF-IR; viii. inibidores da quínase mTOR; ix. antagonistas do receptor de somatostatina; x. inibidores de P13K; xi. inibidores da quínase Raf; xii. inibidores de PKC; xiii. antagonistas de integrina; xiv. moléculas antiangiogênicas endógenas; e xv. PEDF e análogos."COMBINATIONS OF A VEGF RECEIVER INHIBITOR WITH OTHER THERAPEUTIC AGENTS". The present invention relates to a combination therapy for the treatment of patients suffering from diseases characterized by cell proliferation and inflammatory cell infiltration, coronary heart disease, hypertension, kidney disease, diabetes or eye disease and conditions. The patient is treated with a combination of: (a) a VEGF inhibitor compound; and (b) one or more second therapeutic agents selected from the group consisting of: i. angiostatic steroids; ii. photosensitizers; iii. implants containing corticosteroids; iv. AT1 receptor antagonists; v. ACE inhibitors; saw. cyclooxygenase inhibitors; vii. IGF-IR inhibitors; viii. mTOR kinase inhibitors; ix. Somatostatin receptor antagonists; x. P13K inhibitors; xi Raf kinase inhibitors; xii. PKC inhibitors; xiii. integrin antagonists; xiv. endogenous antiangiogenic molecules; and xv. PEDF and analogues.

BRPI0414604-2A 2003-09-23 2004-09-23 combinations of a vegf receptor inhibitor with other therapeutic agents BRPI0414604A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50525503P 2003-09-23 2003-09-23
PCT/EP2004/010701 WO2005027973A2 (en) 2003-09-23 2004-09-23 Combinations of a vegf receptor inhibitor with other therapeutic agents

Publications (1)

Publication Number Publication Date
BRPI0414604A true BRPI0414604A (en) 2006-11-07

Family

ID=34375570

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414604-2A BRPI0414604A (en) 2003-09-23 2004-09-23 combinations of a vegf receptor inhibitor with other therapeutic agents

Country Status (8)

Country Link
EP (1) EP1667721A2 (en)
JP (1) JP2007505939A (en)
CN (1) CN1856326A (en)
AU (1) AU2004273619A1 (en)
BR (1) BRPI0414604A (en)
CA (1) CA2539230A1 (en)
MX (1) MXPA06003164A (en)
WO (1) WO2005027973A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
JP2007530633A (en) * 2004-04-02 2007-11-01 ノバルティス アクチエンゲゼルシャフト VEGF receptor tyrosine kinase inhibitor coated stent
KR20070106036A (en) * 2005-02-25 2007-10-31 노파르티스 아게 Pharmaceutical combination of bcr-abl and raf inhibitors
US20090197922A1 (en) * 2006-01-24 2009-08-06 The University Of Chicago Compositions and methods for treating pulmonary hypertension
EP2012794B1 (en) * 2006-04-13 2014-09-17 The Trustees of Columbia University in the City of New York Compositions and intraluminal devices for inhibiting vascular stenosis
US20090285826A1 (en) * 2006-05-04 2009-11-19 Fovea Pharmaceuticals Sa Combination drugs comprising vegf inhibitor and serine proteases/thrombolytic compounds for treating neovascular disorders
WO2007139943A2 (en) * 2006-05-26 2007-12-06 Ico Therapeutics Inc. Therapeutic drug combinations and delivery systems comprising c-raf kinase antisense polynucleotides for treating ocular diseases and disorders
US20100256136A1 (en) * 2006-07-10 2010-10-07 Pandey Ravindra K Method for Enhancing Pdt Efficacy Using a Tyrosine Kinase Inhibitor
AU2009225434B2 (en) * 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
EP2498806B1 (en) * 2009-11-12 2014-12-31 Ramot at Tel-Aviv University Ltd. Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes
US20120301478A1 (en) 2010-01-14 2012-11-29 Yuichiro Ogura Pharmaceutical for Preventing or Treating Disorders Accompanied by Ocular Angiogenesis and/or Elevated Ocular Vascular Permeability
WO2012105610A1 (en) 2011-02-02 2012-08-09 公立大学法人名古屋市立大学 Medicinal agent for prevention or treatment of diseases associated with intraocular neovascularization and/or intraocular vascular hyperpermeability
CN106581666A (en) * 2016-11-23 2017-04-26 新乡医学院 Application of PEDF in preparing medicine for diabetes bone tissue complication

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2277273C (en) * 1997-01-17 2008-03-25 Merck & Co., Inc. Integrin antagonists
GB0001930D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20040171630A1 (en) * 2001-06-19 2004-09-02 Yuntae Kim Tyrosine kinase inhibitors
US7265134B2 (en) * 2001-08-17 2007-09-04 Merck & Co., Inc. Tyrosine kinase inhibitors
NZ552335A (en) * 2001-10-25 2008-11-28 Novartis Ag Combinations comprising a selective COX-2 inhibitor and a microtubule interfering agent

Also Published As

Publication number Publication date
WO2005027973A2 (en) 2005-03-31
WO2005027973A3 (en) 2005-09-09
JP2007505939A (en) 2007-03-15
EP1667721A2 (en) 2006-06-14
CA2539230A1 (en) 2005-03-31
AU2004273619A1 (en) 2005-03-31
MXPA06003164A (en) 2006-06-05
CN1856326A (en) 2006-11-01

Similar Documents

Publication Publication Date Title
BRPI0414604A (en) combinations of a vegf receptor inhibitor with other therapeutic agents
Moon Recent update of renin-angiotensin-aldosterone system in the pathogenesis of hypertension
MA28935B1 (en) PREPARATION AND USE OF BIPHENYL-4-YL CARBONYLAMINO ACID DERIVATIVES IN THE TREATMENT OF OBESITY
EA200900940A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PYRAZOL-O-GLUCOSIDE DERIVATIVE
BR0015974A (en) Use of levetiracetam, pharmaceutical composition, use of a pharmaceutical composition and methods to treat a patient administered with an amount of at least one compound and a disease and to selectively potentiate the therapeutic effect of a compound
BRPI0206641B8 (en) use of a sterol absorption inhibitor
ATE457166T1 (en) ORAL COMPOSITIONS FOR TREATING DIABETES
WO2000012110A3 (en) Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
JP2003506485A (en) Use of monoamine oxidase inhibitors for the manufacture of a medicament intended for treating obesity
JP2007527875A (en) Methods for inhibiting fibrosis
BR0212078A (en) Method of treating or preventing an amyloid-related disease in a patient, pharmaceutical composition, chemical compound, and use of a compound.
BRPI0608343A2 (en) compound, pharmaceutical composition, and methods for treating or controlling a disease or condition, for enhancing sleep quality, for increasing sleep rem and slow-wave sleep, for reducing fragmentation of sleep patterns, for enhancing cognition for enhancing memory retention, and for treating, controlling, ameliorating or reducing the risk of schizophrenia in a mammalian patient in need thereof
BR0212586A (en) Composition, use of a combination of ipratropium or a salt thereof and xylometazoline or a salt thereof, and methods for the treatment of a condition selected from the group consisting of symptoms associated with the common cold and symptoms associated with rhinitis and to stabilize an aqueous solution of ipratropium or a salt thereof and xylometazoline or a salt thereof
EA200700214A1 (en) MEMANTINE AS AN ADDITIONAL THERAPY FOR ATYPICAL ANTIPSYCHOTIC REMEDIES IN PATIENTS WITH SCHIZOPHRENIA
BR0008687A (en) Methods for the treatment of, and to prevent or control, gastrointestinal disorders, dysfunction of gastrointestinal motility, emesis, and gastro-oesophageal reflux disease in a patient, and pharmaceutical composition
BRPI0510044B8 (en) pharmaceutical composition, and, use of a pharmaceutical composition
EA200501710A1 (en) SUBSTITUTED CARBON ACIDS
NO20055531L (en) Preparation for improved cognition and memory
ATE451361T1 (en) MATERIALS AND METHODS FOR TREATING COAGULATION DISORDERS
BRPI0406749A (en) Methods related to treatment of bowel dysfunction and pharmaceutical composition
ATE451922T1 (en) USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS
Greene et al. Microvascular angiogenesis and the renin-angiotensin system
Vatter et al. Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist shown to be clinically effective for the treatment of cerebral vasospasm. Part II: Effect on endothelinB receptor—mediated relaxation
Fasipe et al. Exercise and vascular function in sedentary lifestyles in humans
JP2612175B2 (en) Prazosin enhancement

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired